ClearPoint Neuro, Inc. (CLPT)
CLPTNASDAQ-CMMedical/Dental Instruments
$9.17
-0.0900 (-0.97%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $9.26 +0.98%
- Market cap
- $296.82m
- P/E
- –
- EPS, last 4 quarters
- $-1.21
- Dividend yield
- –
- Day range
- –
- 52-week range
- $8.27 to $19.63
- Average volume
- –
- Previous close
- $9.26
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $21.50, +134.5% from here
Earnings
next estimate $-0.2300Next report
Dec 2025
-22.7%
Mar 2026
-14.3%
Jun 2026
-31.0%
Sep 2026
+25.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $10.41m | $12.13m | $10.88m | $12.07m |
| Gross profit | $6.40m | $7.76m | $6.71m | $7.06m |
| Operating income | -$7.04m | -$8.48m | -$10.24m | -$6.33m |
| Net income | -$7.79m | -$9.55m | -$11.34m | -$7.46m |
Last four quarters: revenue $45.49m, margin -79.4%, free cash flow -$33.22m
News
8 latest- ClearPoint Neuro (CLPT) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 29, 2026
- ClearPoint Neuro, Inc. Q3 Loss Widens RTTNews · Oct 28, 2026
- What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings CallMarketBeat · Oct 28, 2026
- ClearPoint Neuro, Inc. Reports Third Quarter 2026 Revenue of $12.1 millionFintel · Oct 28, 2026
- ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue EstimatesZacks · Oct 28, 2026
- Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings GrowthZacks · Oct 26, 2026
- AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue EstimatesZacks · Oct 8, 2026
- Alphatec (ATEC) Moves 19.7% Higher: Will This Strength Last?Zacks · Sep 14, 2026
The company
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct central nervous system delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- clearpointneuro.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.